|
Atherosclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Since a crosstalk between AGE and angiotensin II (Ang II) has been proposed in the pathogenesis of accelerated atherosclerosis in diabetes, we examined here whether and how telmisartan, a unique Ang II type 1 receptor blocker (ARB) with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity, could inhibit AGE-induced CRP expression in a human hepatoma cell line, Hep3B cells.
|
17004092 |
2006 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator activated receptor gamma (PPARgamma) modulates atherosclerosis by its anti-inflammatory and anti-protease activity.
|
16311343 |
2005 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
|
16259527 |
2005 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, as more PPARgamma targeted pathways are revealed such as bone homeostasis, atherosclerosis and longevity, it is most certain that the PPARgamma thrifty gene hypothesis will evolve to incorporate these.
|
15667578 |
2005 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
LHGDN |
In conclusion, stimulation of CYP27A1 by PPARgamma may represent a key previously unrecognized mechanism by which PPARgamma protects against atherosclerosis.
|
15533057 |
2005 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Although activation of PPARgamma appears to have beneficial effects on atherosclerosis and heart failure, it is still largely uncertain whether PPARgamma ligands prevent the development of cardiovascular diseases.
|
12861348 |
2003 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor involved in such cellular processes as adipogenesis, inflammation, atherosclerosis, cell cycle control, apoptosis, and carcinogenesis.
|
12364466 |
2002 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results add to the concern that the clinical use of insulin-sensitizing PPARgamma agonists (i.e. thiazolidinediones) to treat Type 2 Diabetes could exacerbate atherosclerosis, and highlight the need for clinical trials that address this issue.
|
12417276 |
2002 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Recent studies showed that PPARgamma is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis.
|
11500181 |
2001 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
This issue is important because thiazolidinediones, which are ligands for PPARgamma, have recently been approved for the treatment of type 2 diabetes, a state of accelerated atherosclerosis.
|
11231915 |
2001 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Pharmacological activation of PPARgamma expressed in VSMCs inhibits their proliferation and migration, potentially limiting restenosis and atherosclerosis.
|
10725292 |
2000 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We report here that the PPARgamma-specific agonists rosiglitazone and GW7845 strongly inhibited the development of atherosclerosis in LDL receptor-deficient male mice, despite increased expression of the CD36 scavenger receptor in the arterial wall.
|
10953027 |
2000 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our results establish a role for PPARgamma in the regulation of EC gene expression, with important implications for the clinical links between obesity and atherosclerosis.
|
10073956 |
1999 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The role of oxidized low-density lipoprotein in the activation of peroxisome proliferator-activated receptor gamma: implications for atherosclerosis.
|
10101923 |
1999 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|